TREATMENT-EXPERIENCED BREAST CANCER
|
|
- Molly McCormick
- 8 years ago
- Views:
Transcription
1 TREATMENT-EXPERIENCED BREAST CANCER * Robert J. Ignoffo, PharmD, FASHP, FCSHP ABSTRACT Survival rates of metastatic breast cancer have improved considerably in the past 2 decades. However, the median survival of patients with metastatic breast cancer remains 2 to 3 years, with only 5% to 10% achieving longterm remission. Treatment goals for this population should be primarily palliative, designed to maintain quality of life and prolong survival or at least delay disease progression. Primary therapies include hormonal options, systemic chemotherapy, and targeted therapies. Prognosis varies based on the tumor s Scarff-Bloom- Richardson grade, hormonal and human epidermal growth factor receptor type 2 expression, previous response to hormonal therapies and/or chemotherapy, length of time before disease progression, existing comorbidities, and volume and site of metastases. Choosing the appropriate therapy depends on the hormonal receptor status of the tumor, comorbidities (particularly liver or kidney abnormalities), disease severity, and location of metastases, as well as patient preference. Growth factor inhibitors, combinations of hormonal and targeted therapies, and newer agents, such as kinesin spindle protein inhibitors and epothilones, offer additional options for the near future. (Adv Stud Pharm. 2007;4(13): ) *Based on a presentation by Dr Ignoffo at a roundtable held in Scottsdale, Arizona, on September 6, Emeritus Clinical Professor, University of California at San Francisco, San Francisco, California; Professor of Pharmacy, College of Pharmacy, Touro University California, Vallejo, California. Address correspondence to: Robert J. Ignoffo, PharmD, FASHP, FCSHP, Professor of Pharmacy, College of Pharmacy, Touro University California, 1310 Johnson Lane, Vallejo, CA Robert.Ignoffo@touro.edu. TREATMENT-EXPERIENCED BREAST CANCER Although the mortality rate from breast cancer in the United States has steadily declined over the past 20 years, 1% to 5% of women with breast cancer will present with metastatic disease at the time of diagnosis. Another 10% to 15% will relapse with distant metastases, primarily to the bone, liver, or lung. Seventy-five percent of metastatic breast cancer cases develop within 5 years of the original diagnosis. Metastatic breast cancer is not a curable disease, although 5-year survival rates are increasing. 1,2 Metastatic breast cancer is a disease with wide heterogeneity. Some patients experience a rapid course of metastases and physical decline despite systemic treatment, whereas others follow an indolent course with long periods of stability. These latter patients tend to be postmenopausal with estrogen receptor (ER)-positive tumors. They may survive in the absence of active treatment for more than 10 years. However, the median survival of patients with metastatic breast cancer is 2 to 3 years, 2,3 and only 5% to 10% of patients achieve long-term remission (>5 years), with patients who respond to chemotherapy exhibiting a longer survival. 4,5 Overall, just 5% to 15% of women with metastatic breast cancer achieve a complete response. 4,6 Prognostic factors for metastatic breast cancer include the volume and site of metastases. Patients with metastases to the skin, lymph nodes, or bone tend to survive longer than those with visceral metastases to the lungs, liver, or brain. 7 Comorbidities, such as diabetes, arthritis, or cardiovascular disease, also play a significant role in survival. Patients with more than 2 comorbidities tend to exhibit a poorer survival rate. However, comorbidities are also an independent prognostic factor given their tendency to impact patients ability to tolerate therapy or a therapeutic dose, either of which may result in a poorer clinical response Vol. 4, No. 13 December 2007
2 A patient s response to previous therapy, whether systemic or hormonal, also affects prognosis. A longer previous disease-free interval predicts a better prognosis. Finally, tumor receptor status plays an important role in prognosis. Women with ER-positive tumors generally have increased survival compared to those with ER-negative tumors and human epidermal growth factor receptor type 2 (HER2)-receptor amplification, who tend to have a more aggressive course of disease. 3 ER-positive tumors also tend to respond better to hormonal therapies, both chemical and surgical. Overall, approximately 50% to 60% of ER-positive tumors respond to hormonal therapies compared to approximately 6% of ER- or progesterone receptor (PR)-negative tumors. 3 Approximately 70% of women with breast cancer, most of them postmenopausal, have ER-positive tumors. In contrast to ER-positive tumors, only 20% to 30% of women exhibit tumors with HER2 amplification/overexpression. This tumor type appears in approximately 33% of women with breast cancer aged younger than 50 and predicts a poor response to hormonal therapy. However, HER2 amplification predicts a good response to chemotherapy in metastatic disease and in the adjuvant setting, particularly the anthracycline doxorubicin and the taxane paclitaxel. 3 TREATMENT GOALS AND OPTIONS IN METASTATIC BREAST CANCER The treatment goals for metastatic breast cancer are to palliate symptoms, prolong survival, increase progression-free survival or delay disease progression, and improve the quality of life for the patient. 2 In rare cases, surgery or radiotherapy may be attempted for isolated metastases, but the primary therapies used are systemic chemotherapy, endocrine therapy, biologic agents, and bisphosphonates (for bone metastases). Hormonal options and chemotherapy are the standard treatments, although many biologic targeted agents are exhibiting promise for this stage of cancer. In some instances, women may opt for alternative therapies in addition to traditional treatments. 3 The selection of appropriate therapy depends on several patient and tumor factors. The factor most often driving endocrine therapy is whether a patient has an ER on the cancer cells. In addition, patients who have multiple comorbidities or vital organ abnormalities, particularly renal or hepatic dysfunction, have a high risk of chemotherapy toxicities. Other factors that suggest hormonal therapy as an initial option include a previous response to endocrine therapy, evidence of indolent disease, postmenopausal status, and lack of visceral involvement. In contrast, patients considered good candidates for chemotherapy include those with aggressive disease, visceral involvement, ER-negative status, and HER2-positive tumors. 2 The Figure depicts an algorithm for the treatment of advanced breast cancer and the 5 most commonly used options. As the Figure demonstrates, patients with ER- and/or PR-positive tumors generally begin treatment with hormonal therapies. If they become refractory to hormonal therapies, or if the tumors are ER and/or PR negative, patients then initiate chemotherapy. If the tumor also expresses HER2, trastuzumab is added to chemotherapy. However, if the patient is triple negative with no tumor expression of estrogen, progesterone, or HER2, chemotherapy alone is the preferred option. 7 HORMONAL THERAPY The antiestrogen tamoxifen is typically the firstline hormonal therapy for premenopausal women with metastatic breast cancer. If patients have a risk factor that does not allow for tamoxifen therapy, then ovarian ablation (surgical or radiation therapy), or medical oophorectomy with luteinizing hormone-releasing Figure. Treatment Algorithm for Metastatic Breast Cancer* Advanced Breast Cancer Requiring Therapy 1 2 ER and/or PR Positive Hormonal treatments ER and/or PR Negative Chemotherapy Refractory to hormonal therapy HER2 Positive Chemotherapy + trastuzumab HER2 Negative Chemotherapy *1, 2, 3, 4, 5 = scenarios. ER = estrogen receptor; HER2 = human epidermal growth factor receptor 2; PR = progesterone receptor. Reprinted with permission from Mayer and Burstein. Hematol Oncol Clin North Am. 2007;21: University of Tennessee Advanced Studies in Pharmacy 383
3 hormone (LHRH) analogues (eg, goserelin or leuprolide) may be used. If the patient initially responds but then becomes refractory, whichever option has not already been attempted may be used. For instance, if the patient is refractory to surgical or medical oophorectomy, begin an antiestrogen; if she becomes refractory on an antiestrogen, move to ovarian ablation or LHRH analogue. If ovarian function ceases after first-line therapy, the patient should continue on tamoxifen. If relapse occurs after all approaches, third-line therapy options include fulvestrant or progestins (eg, megestrol acetate or medroxyprogesterone acetate), or, possibly, aromatase inhibitors (eg, anastrozole, letrozole, or exemestane). However, the usefulness of aromatase inhibitors in premenopausal women remains questionable. 3 Aromatase inhibitors, as well as antiestrogens, are indicated as first-line hormonal therapies for postmenopausal women, followed by progestins or androgens (fluoxymesterone) if disease recurs. 3 Adverse effects of tamoxifen include hot flashes (64%), fluid retention (32%), vaginal discharge (30%), nausea (26%), irregular menses (25%), increased bilirubin levels (2%), increased creatinine levels (2%), thrombocytopenia (2%), deep vein thrombosis (0.8%), pulmonary embolism (0.5%), and skin changes (19%). 8 Adverse effects of progesterone include mild fluid retention, menstrual irregularities, and nausea. The aromatase inhibitors may result in arthralgia (15% 20%), hot flashes, blood clots (1%), and edema (7%). Finally, the most common adverse effects of gonadotropin-releasing hormone (GnRH) agonist inhibitors are hot flashes (50%), decreased libido (9%), and gynecomastia (9%) SYSTEMIC CHEMOTHERAPY Although many chemotherapy regimens show activity in metastatic breast cancer, no single agent or combination has emerged as the standard. Instead, drug selection is based on adverse effect profile, prior therapy, and patient preferences. 3,7,12 In most instances, chemotherapy begins with an anthracycline or taxane. On average, these drugs produce a 13% complete remission rate and approximately a 30% to 40% partial remission with a median duration of response of approximately 10 months. 3,7,13 However, with each successful chemotherapy treatment, the response rate and duration of response drops. There does not appear to be a dose-response curve for metastatic breast cancer, thus, high-dose chemotherapy is not recommended. 3,7,13 In certain situations, adding hormonal therapy to systemic chemotherapy in patients with widely metastatic disease may prolong survival, but this outcome is variable. 3,7,13 DURATION AND DISCONTINUATION OF CHEMOTHERAPY Once chemotherapy begins, most patients continue until disease progression or prohibitive toxicity occurs. In patients with indolent disease and an extended period of response, a chemotherapy holiday of up to 1 year or until recurrence is an option. Signs of overt tumor recurrence are typically addressed with a change to a different chemotherapy regimen. It is not unusual for patients with metastatic breast cancer to undergo 3 to 4 chemotherapy regimens COMMON CHEMOTHERAPY TREATMENT REGIMENS The typical chemotherapy regimens for metastatic breast cancer include the anthracyclines, taxanes, fluoropyrimidines, vinorelbine, and gemcitabine. The Table depicts the recommended dosing and adverse effects for each chemotherapy. TARGETED THERAPIES To date, trastuzumab is the only targeted therapy established in the treatment of metastatic breast cancer. As a single agent, it does not appear as effective as chemotherapy, producing only a 17% to 32% partial response. However, in combination with docetaxel or capecitabine, the response rate and duration of response are higher (45% 70%, with some complete responses). Adverse effects include coronary heart failure, asthenia, headache, insomnia, dizziness, rash, rhinitis, pharyngitis, nausea/vomiting, diarrhea, anorexia, back pain, cough, dyspnea, sinusitis, and infusional toxicity. 31 Lapatinib, an oral agent, is a small-molecule, reversible inhibitor of the intracellular tyrosine kinase domain of 2 members of the HER family, HER1 and HER2. 32 The US Food and Drug Administration recently approved it in combination with capecitabine for patients whose cancers had not responded to trastuzumab or other therapies. Potential adverse effects include arrhythmia (rare), extreme dizziness or 384 Vol. 4, No. 13 December 2007
4 fainting, severe diarrhea, and white patches or sores inside the mouth or on the lips. 31 The anti-vascular endothelial growth factor monoclonal antibody bevacizumab, already used as part of chemotherapy regimens for colorectal cancer, may be beneficial in the treatment of metastatic breast cancer. One trial showed that combining bevacizumab with capecitabine resulted in a greater response rate than bevacizumab alone (19.8% vs 9.1%, P =.001). However, the combination did not affect the primary Table. Chemotherapy Options in Metastatic Breast Cancer Chemotherapy Dosage Response Rate Toxicities Anthracyclines Doxorubicin 18, mg/m2 IV Q 3 wk Stomatodynia, nausea/vomiting, mucositis, cardiac toxicities, or 15 mg/m2/wk and alopecia Epirubicin mg/m2 IV Q 3 wk or 36% 41% Stomatodynia syndrome, nausea/vomiting, mucositis, cardiac mg/m2/wk toxicities, and alopecia (better tolerated in the elderly than gemcitabine and doxorubicin, particularly in terms of bone marrow toxicities) 21 Pegylated liposomal mg/m2 IV monthly Less gastrointestinal, cardiac, and hand-foot syndrome doxorubicin 21 toxicity than doxorubicin and epirubicin Taxanes Paclitaxel 19, mg/m2 IV Q 3 wk 32% 43% (first-line) or Stomatodynia syndrome, peripheral neurotoxicity, alopecia, 22% 29% (second-line) fluid-retention syndrome, and hypersensitivity reactions* mg/m2 IV weekly 50% 55% response rate (dose dense) (first- and second-line) 23 Docetaxel mg/m2 IV Q 3 wk Stomatodynia syndrome, mucositis, fluid-retention 48% (first-line) syndrome, alopecia, and nail abnormalities Greater bone marrow toxicity than with paclitaxel Fluoropyrimidines Capecitabine (oral) 25, mg/m2 in 2 daily 30% 37% (first line) Mucositis, diarrhea, hand-foot syndrome, and mild bone doses, 14 of 21 d marrow suppression mg/m2 BID on d ~40% 70% (mean IV docetaxel (75 mg/m2) on duration of response d 1 Q 21 days for patients 6 9 mo) with progressive metastatic breast cancer previously treated with anthracycline-based chemotherapy 27 Other Chemotherapies Vinorelbine mg/m2 IV weekly 25% 40% (first line) Myelosuppression, constipation, and neuropathy (particularly in taxane-treated patients) Gemcitabine mg/m2 IV for 15% 37% (first line) Hematologic, nausea, rash, fatigue, and flu-like symptoms 3 4 wk Greater toxicity in the elderly *Toxicities differ based on cycle of therapy. Greater neurotoxicity with weekly dosing; greater bone marrow toxicities with 3-week dosing. US FDA-approved daily dose is 2500 mg/m 2 but high levels of toxicity generally require a reduced dosage, which appears to have minimal effect on efficacy. 30 A lower dose is preferred in the elderly. 26 Including cohort of elderly. Particularly useful in anthracycline- and taxane-refractory patients. FDA = Food and Drug Administration; IV = intravenous. Data from Paridaens et al 18 ; Sledge et al 19 ; Gasparini et al 20 ; O Shaughnessy 21 ; Seidman et al 22 ; Seidman et al 23 ; Stemmler et al 24 ; O Shaughnessy et al 25 ; Bajetta et al 26 ; O Shaughnessy et al 27 ; Zelek et al 28 ; Feher et al 29 ; Ershler. 30 University of Tennessee Advanced Studies in Pharmacy 385
5 endpoint of progression-free survival (4.86 vs 4.17 months, hazard ratio 0.98) or overall survival (15.1 vs 14.5 months). Bevacizumab is also under investigation in combination with gemcitabine or vinorelbine for the treatment of metastatic breast cancer. 31 Another option is metronomic chemotherapy with frequent oral, low-dose administration, particularly with cyclophosphamide (1 mg/kg/day), often in combination with hormonal therapy. This method results in minimal toxicity. Thus, it is better tolerated and may be particularly beneficial in the elderly. 33 NOVEL OR INVESTIGATIONAL AGENTS Clinical trials with growth factor inhibitors, a combination of tamoxifen and lapatinib, and newer agents such as the kinesin spindle protein inhibitor, ispinesib, are ongoing. 31 One exciting new class is the epothilones, which is exhibiting excellent response rates in chemotherapy-resistant populations In October 2007, ixabepilone became the first epothilone approved for marketing in the United States. 38 It is indicated for the treatment of metastatic or locally advanced breast cancer in combination with capecitabine in patients who failed an anthracycline and a taxane, and as a monotherapy for the treatment of metastatic or locally advanced breast cancer in patients who failed an anthracycline, a taxane, and capecitabine. The product information carries a black box warning that ixabepilone in combination with capecitabine is contraindicated in patients with aspartate aminotransferase or alanine aminotransferase greater than 2.5 x upper limit of normal (ULN) or bilirubin greater than 1 x ULN due to increased risk of toxicity and neutropenia-related death. 39 CONCLUSIONS Several new agents for the treatment of metastatic breast cancer are in late-stage clinical trials and may be available soon. They should continue to improve survival in patients with metastatic breast cancer. DISCUSSION Dr Zamboni: What percentage of patients with either premenopausal or postmenopausal metastatic breast cancer are patients who are triple negative with negative ER, PR, and HER2 receptors? Dr Ignoffo: Probably around 8% to 10%. It is very low. Dr Zamboni: I assume they do the worst? Dr Ignoffo: Generally. But I have not seen a study examining the clinical course of just these patients. Dr Adel: There are no hormonal options for these patients. They start on chemotherapy immediately. Usually, the options are limited for these patients. According to some clinical trials, epothilones showed some activity in patients whose tumors were triple negative. We are seeing some efficacy, but we do not know how effective it is. I also want to add one thing about aromatase inhibitors: the importance of recognizing the increase in triglycerides in clinical trials of women taking aromatase inhibitors. Dr Medina: However, the major side effect of aromatase inhibitors is osteoporosis. As far as the thirdline hormonal treatments, we usually change to systemic therapy instead of using third-line hormonal options in our patients. Mr Solimando: Do you even get to second line? In my clinics, the women get a trial of tamoxifen, and if they fail that, they go right to chemotherapy. Dr Medina: It depends on how long a response we get to the hormonal therapy. If the patient responds for 1 year, and then fails, we will try a second hormonal approach. It also depends on whether they have visceral or bone-only metastatic disease. Mr Solimando: In premenopausal women, we see them start progressing after 3 or 4 months on tamoxifen. At that point, they usually go right to chemotherapy. In fact, I think some oncologists are actually going straight to systemic chemotherapy in this population figuring they will need to use it early in the treatment cycle anyway. As far as the third-line hormonal treatments, we usually change to systemic therapy instead of using third-line hormonal options in our patients. Dr Medina: And certainly aromatase inhibitors are not used in this population outside of a clinical trial. And most of these trials are conducted in combination with ovarian suppression. Thus, using the aromatase inhibitors as a third-line hormonal treatment, even with tamoxifen or GnRH antagonists to block both sources of estrogen, or as a single agent in premenopausal women, is just not done much. Dr Waddell: Is anyone seeing patients taking these aromatase inhibitors or tamoxifen who self-treat their hot flashes with alternative therapies? Dr Ignoffo: Yes. There have been many trials looking at black cohosh, for instance, published in the Journal of Clinical Oncology and other journals, showing some benefit. Some patients try vitamin E or other 386 Vol. 4, No. 13 December 2007
6 alternatives. There have been no good studies, to my knowledge, showing these options have been able to control hot flashes well. Dr Waddell: But what should community pharmacists tell patients who ask about these plant-based options? Dr Ignoffo: They should recommend against it because we do not know what they do in an ER-positive patient. I have not personally seen cases in which they exacerbated the disease, but it does not sound like the appropriate thing to do. Dr Kuhn: Which is better in the metastatic setting: paclitaxel as a single agent every 3 weeks or weekly? Dr Ignoffo: This should be taken into a randomized trial. Just looking at the numbers, it appears that the weekly dosing is approximately 10% to 15% better. But to know if it is truly better, we have to await the results of a big clinical trial. Still, it is an option, although I am not ready to make that jump to saying it is the preferred option. Dr Kuhn: In my opinion, although you can make a case for the 3-week protocol in combination with other drugs, I would never recommend the 3-week schedule of paclitaxel alone for patients with metastatic cancer. Dr Waddell: Also, you have to remember that these are patients with metastatic cancer with lives to live. If it turns out that the toxicity and efficacy is no different, than certainly the patient would rather come in every 3 weeks rather than once every week. REFERENCES 1. Giordano SH, Buzdar AU, Smith TL, et al. Is breast cancer survival improving? Cancer. 2004;100: Hayes DF. Patient information: chemotherapy and herceptin (trastuzumab) for metastatic breast cancer. UpToDate. Available at: asp?file=cancer/8347. Accessed September 26, Margolese RG, Hortobagyi GN, Buchholz TA. Neoplasms of the breast. In: Kufe DW, Pollock RE, Weichselbaum RR, et al, eds. Holland-Frei Cancer Medicine. 6th ed. Hamilton, Ontario: BC Decker Inc; Rahman ZU, Frye DK, Smith TL, et al. Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: a reference. Cancer. 1999;85: Canellos GP, DeVita VT, Gold GL, et al. Combination chemotherapy for advanced breast cancer: response and effect on survival. Ann Intern Med. 1976;84: Decker DA, Ahmann DL, Bisel HF, et al. Complete responders to chemotherapy in metastatic breast cancer. Characterization and analysis. JAMA. 1979;242: Mayer EL, Burstein HJ. Chemotherapy for metastatic breast cancer. Hematol Oncol Clin North Am. 2007;21: Drugs.com. Tamoxifen. Available at: Accessed November 27, Goserelin [prescribing information]. Cheshire, UK: AstraZeneca; Leuprolide [prescribing information]. Lake Forest, IL: TAP Pharmaceuticals Inc; Burstein HJ. Aromatase inhibitor-associated arthralgia syndrome. Breast. 2007;16: Aisner J, Weinberg V, Perloff M, et al. Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B. J Clin Oncol. 1987;5: Fossati R, Confalonieri C, Torri V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol. 1998;16: Coates A, Gebski V, Bishop JF, et al. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med. 1987;317: Gennari A, Amadori D, De Lena M, et al. Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. J Clin Oncol. 2006;24: Muss HB, Case LD, Richards F 2nd, et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. N Engl J Med. 1991;325: Nooij MA, de Haes JC, Beex LV, et al. Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients. Clinical outcomes and oncologists preferences. Eur J Cancer. 2003;39: Paridaens R, Biganzoli L, Bruning P, et al. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol. 2000;18: Sledge GW, Neuberg D, Bernardo P, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol. 2003;21: Gasparini G, Dal Fior S, Panizzoni GA, et al. Weekly epirubicin versus doxorubicin as second line therapy in advanced breast cancer. A randomized clinical trial. Am J Clin Oncol. 1991;14: O Shaughnessy JA. Pegylated liposomal doxorubicin in the treatment of breast cancer. Clin Breast Cancer. 2003;4: Seidman AD, Tiersten A, Hudis C, et al. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol. 1995;13: Seidman AD, Hudis CA, Albanell J, et al. Dose-dense therapy University of Tennessee Advanced Studies in Pharmacy 387
7 with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol. 1998;16: Stemmler HJ, Gutschow K, Sommer H, et al. Weekly docetaxel (Taxotere) in patients with metastatic breast cancer. Ann Oncol. 2001;12: O Shaughnessy JA, Blum J, Moiseyenko V, et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda(r)) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as firstline therapy for advanced/metastatic breast cancer. Ann Oncol. 2001;12: Bajetta E, Procopio G, Celio L, et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol. 2005;23: O Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002;20: Zelek L, Barthier S, Riofrio M, et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer. 2001;92: Feher O, Vodvarka P, Jassem J, et al. First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study. Ann Oncol. 2005;16: Ershler WB. Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer. Oncologist. 2006;11: Tripathy D. Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: underlying rationale and results of clinical trials. Oncologist. 2007;12: Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355: Burstein H, Spigel D, Kindsvogel K, et al. Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: a randomized phase II study. Breast Cancer Res Treat. 2005;94:S Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS ) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2007;25: Thomas E, Tabernero J, Fornier M, et al. Phase II clinical trial of ixabepilone (BMS ), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol. 2007;25: Roche H, Yelle L, Cognetti F, et al. Phase II clinical trial of ixabepilone (BMS ), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol. 2007;25: National Institute of Health. ClinicalTrials.Gov. Available at: Accessed September 26, Medical News Today. FDA approves Ixempra(tm) (ixabepilone), a semi-synthetic analog of epothilone b, for the treatment of advanced breast cancer. October 17; Available at: Accessed October 29, Ixabepilone [prescribing information]. Princeton, NJ: Bristol- Myers Squibb; Vol. 4, No. 13 December 2007
Breast Cancer. Breast Cancer Page 1
Breast Cancer Summary Breast cancers which are detected early are curable by local treatments. The initial surgery will give the most information about the cancer; such as size or whether the glands (or
More informationEverolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationTreatment of Metastatic Breast Cancer: Endocrine Therapies. Robert W. Carlson, M.D. Professor of Medicine Stanford University
Treatment of Metastatic Breast Cancer: Endocrine Therapies Robert W. Carlson, M.D. Professor of Medicine Stanford University MDACC Experience with FAC in Chemotherapy-Naive MBC Greenberg et al, J Clin
More informationCorporate Medical Policy
Corporate Medical Policy Ado-Trastuzumab Emtansine (Trastuzumab-DM1) for Treatment of File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ado_trastuzumab_emtansine_(trastuzumab-dm1)_for_treatment_of_her-2_positivemalignancies
More informationNew Treatment Options for Breast Cancer
New Treatment Options for Breast Cancer Brandon Vakiner, PharmD., BCOP Clinical Pharmacy Specialist - Oncology The University of Iowa Hospitals and Clinics Assistant Professor (Clinical) University of
More informationGUIDELINES ADJUVANT SYSTEMIC BREAST CANCER
GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER Author: Dr Susan O Reilly On behalf of the Breast CNG Written: December 2008 Agreed at CNG: June 2009 & June 2010 Review due: June 2011 Guidelines Adjuvant Systemic
More informationCytotoxic Therapy in Metastatic Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Cytotoxic Therapy in Metastatic Breast Cancer Cytotoxic Therapy in Metastatic Breast Cancer Version 2002: von Minckwitz Versions
More informationI will be having surgery and radiation treatment for breast cancer. Do I need drug treatment too?
What is node-positive breast cancer? Node-positive breast cancer means that cancer cells from the tumour in the breast have been found in the lymph nodes (sometimes called glands ) in the armpit area.
More informationLow dose capecitabine is effective and relatively nontoxic in breast cancer treatment.
1 Low dose capecitabine is effective and relatively nontoxic in breast cancer treatment. John T. Carpenter, M.D. University of Alabama at Birmingham NP 2508 1720 Second Avenue South Birmingham, AL 35294-3300
More informationDrug/Drug Combination: Bevacizumab in combination with chemotherapy
AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Chemotherapy for the Treatment of Metastatic Breast Cancer Previously Treated with Cytotoxic Chemotherapy
More informationChemotherapy or Not? Anthracycline or Not? Taxane or Not? Does Density Matter? Chemotherapy in Luminal Breast Cancer: Choice of Regimen.
Chemotherapy in Luminal Breast Cancer: Choice of Regimen Andrew D. Seidman, MD Attending Physician Breast Cancer Medicine Service Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Cornell
More informationGemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer
Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer Review Article [1] December 01, 2003 By George W. Sledge, Jr, MD [2] Gemcitabine (Gemzar) and paclitaxel show good activity as single
More informationMetastatic Breast Cancer...
DIAGNOSIS: Metastatic Breast Cancer... What Does It Mean For You? A diagnosis of metastatic breast cancer can be frightening. It raises many questions and reminds us of days past when cancer was such a
More informationAdvances In Chemotherapy For Hormone Refractory Prostate Cancer. TAX 327 study results & SWOG 99-16 study results presented at ASCO 2004
Ronald de Wit Rotterdam Cancer Institute The Netherlands Advances In Chemotherapy For Hormone Refractory Prostate Cancer TAX 327 study results & SWOG 99-16 study results presented at Slide 1 Prostate Cancer
More informationWhat s New With HER2?
What s New With HER2? Trastuzumab emtansine and pertuzumab for metastatic breast cancer Lindsay Livingston Pharmacist CancerCare Manitoba October 3, 2014 Presenter Disclosure Faculty: Lindsay Livingston
More informationUpdate in Hematology Oncology Targeted Therapies. Mark Holguin
Update in Hematology Oncology Targeted Therapies Mark Holguin 25 years ago Why I chose oncology People How to help people with possibly the most difficult thing they may have to deal with Science Turning
More informationBreast Cancer Educational Program. June 5-6, 2015
Breast Cancer Educational Program June 5-6, 2015 Adjuvant Systemic Therapy For Early Breast Cancer: Who, What and for How Long? Debjani Grenier MD, FRCPC Medical Oncologist Disclosures Advisory Board Member:
More informationStrength of Study End Point(s): Progression-free survival
AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Paclitaxel for the First-line Treatment of Metastatic Breast Cancer Drug/Drug Combination: Bevacizumab and
More informationMetastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011
Metastatic Breast Cancer 201 Carolyn B. Hendricks, MD October 29, 2011 Overview Is rebiopsy necessary at the time of recurrence or progression of disease? How dose a very aggressive treatment upfront compare
More informationBreast Cancer Update 2014 Prevention, Risk, and Treatment of Early Stage Breast Cancer. Kevin R. Fox, MD University of Pennsylvania
Breast Cancer Update 2014 Prevention, Risk, and Treatment of Early Stage Breast Cancer Kevin R. Fox, MD University of Pennsylvania Prevention of Breast Cancer Accepted treatments Tamoxifen (premenopausal
More informationJanuary 2013 LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Summary. Contents
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/paclitaxel for cancer Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/ paclitaxel for
More informationBreastCancerTrials.org History Form: Metastatic Breast Cancer ABOUT ME
BreastCancerTrials.org History Form: Metastatic Breast Cancer This form is for patients with metastatic breast cancer who were: Were recently diagnosed with metastatic breast cancer (cancer that has spread
More informationCheckMate -057, a Pivotal III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early
April 21, 2015 CheckMate -057, a Pivotal III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early Opdivo Demonstrates Superior Overall Survival Compared to Docetaxel in Patients with Previously-Treated
More informationIs the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study
Turkish Journal of Cancer Volume 34, No.1, 2004 19 Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study MUSTAFA ÖZDO AN, MUSTAFA SAMUR, HAKAN BOZCUK, ERKAN ÇOBAN,
More informationFOURTH EDITION. Metastatic Breast Cancer
FOURTH EDITION Metastatic Breast Cancer Dedicated to all the people with metastatic breast cancer who shared their stories, experiences and wisdom to make this guide possible. Table of Contents CHAPTER
More informationBREAST CANCER WHAT HAPPENS AFTER SURGERY?
BREAST CANCER WHAT HAPPENS AFTER SURGERY? Contents: Planning further treatment Medical management of breast cancer Support and follow up Questions to ask your surgeon or oncologist Planning further treatment
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PS Inj - Alimta Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antifolates Client: PS Inj Approval Date: 8/2/2004 Revision Date: 12/5/2006 I. BENEFIT
More informationTreating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer
Breast Studies Adjuvant therapy after surgery Her 2 positive Breast Cancer B 52 Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients with Hormone
More informationChemotherapy for metastatic breast cancer
Annals of Oncology 16 (Supplement 4): iv23 iv27, 2005 doi:10.1093/annonc/mdi904 Chemotherapy for metastatic breast cancer S. Barni* & M. Mandalà Division of Medical Oncology, Treviglio Hospital, Treviglio,
More informationMETASTATIC BREAST CANCER
METASTATIC BREAST CANCER Executive Summary Metastatic breast cancer is defined as disease beyond the breast and regional lymph nodes. Although metastatic breast cancer is generally incurable, patients
More informationOne of the most mature trials that examined PROCEEDINGS. Hormone Therapy in Postmenopausal Women With Breast Cancer * William J.
Hormone Therapy in Postmenopausal Women With Breast Cancer * William J. Gradishar, MD ABSTRACT *Based on a presentation given by Dr Gradishar at a roundtable symposium held in Baltimore on June 28, 25.
More informationCancer patients waiting for potentially live-saving treatments in UK
Cancer patients waiting for potentially live-saving treatments in UK 29 May 2005 UK patients are waiting too long for new treatments, according to a 'Dossier of Delay' compiled by information charity CancerBACUP.
More informationMetastatic Breast Cancer: The Art and Science of Systemic Therapy. Vallerie Gordon MD, FRCPC Medical Oncologist CancerCare Manitoba
Metastatic Breast Cancer: The Art and Science of Systemic Therapy Vallerie Gordon MD, FRCPC Medical Oncologist CancerCare Manitoba Presenter Disclosure Faculty: Dr. Vallerie Gordon Relationships with commercial
More informationInformation and Insight into Breast Cancer in China. White Paper. by Neesha Suvarna, PhD Consultant, Kantar Health November 2011
White Paper Catalysts driving successful decisions in life sciences. Information and Insight into Breast Cancer in China by Neesha Suvarna, PhD Consultant, Kantar Health November 2011 www.kantarhealth.com
More informationMiquel Àngel Seguí Palmer
Miquel Àngel Seguí Palmer HER2+ Breast Cancer is characterized by overexpression of HER2 receptors HER2+ Breast Cancer is characterized by overexpression of HER2 receptors HER2+ status is associated with
More informationCellular, Molecular, and Biochemical Targets in Breast Cancer
Cellular, Molecular, and Biochemical Targets in Breast Cancer Kristy Kummerow Ingrid Meszoely December 12, 2012 VUMC Resident Bonus Conference One size fits all surgical treatment of breast cancer Wilhelm
More informationCLINICAL POLICY Department: Medical Management Document Name: HER2 Breast Cancer Treatments
Page: 1 of 11 Specialist Review: Revised: 06/13 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review
More informationIssues Concerning Development of Products for Treatment of Non-Metastatic Castration- Resistant Prostate Cancer (NM-CRPC)
Issues Concerning Development of Products for Treatment of Non-Metastatic Castration- Resistant Prostate Cancer (NM-CRPC) FDA Presentation ODAC Meeting September 14, 2011 1 Review Team Paul G. Kluetz,
More informationRecommendation Strength Strong, supported by the evidence and expert consensus. Recommendation Benefit/Harm Evidence Quality
CHEMO- AND TARGETED THERAPY FOR WOMEN WITH HER2 NEGATIVE (OR UNKNOWN) ADVANCED BREAST Benefit/Harm Evidence Quality 1: Endocrine therapy, rather than chemotherapy, should be offered as the standard firstline
More informationAttached from the following page is the press release made by BMS for your information.
July 22, 2015 CheckMate -025 (global clinical trial), a Pivotal Phase III Opdivo (nivolumab) Renal Cancer Trial Stopped Early (PRINCETON, NJ, July 20, 2015) Bristol-Myers Squibb Company (NYSE:BMY) announced
More informationBreastCancerTrials.org History Form: Completed Treatment for Breast Cancer ABOUT ME
BreastCancerTrials.org History Form: Completed Treatment for Breast Cancer This form is for patients with DCIS or early stage invasive cancer who are: On hormone therapy after breast cancer surgery Or
More informationClinical Management Protocol Chemotherapy Breast Cancer. Protocol for Planning and Treatment
Protocol for Planning and Treatment The process to be followed when a course of chemotherapy is required to treat: BREAST CANCER Patient information given at each stage following agreed information pathway
More informationNational Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007
Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search.
More informationBREAST CANCER UPDATE C H R I S S Z Y A R T O, D O G E N E S E E H E M A T O L O G Y O N C O L O G Y F L I N T, M I
BREAST CANCER UPDATE C H R I S S Z Y A R T O, D O G E N E S E E H E M A T O L O G Y O N C O L O G Y F L I N T, M I Overview Why is it important to understand breast cancer? Choosing wisely Appropriateness
More informationBREAST CANCER (RECURRENT OR METASTATIC) TREATMENT REGIMENS (Part 1 of 5)
BREAST CANCER (RECURRENT METASTATIC) TREATMENT S (Part 1 of 5) Clinical Trials: The NCCN recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer therapy selection,
More informationManagement of Metastatic Breast Cancer
ONCOLOGY BOARD REVIEW MANUAL STATEMENT OF EDITORIAL PURPOSE The Hospital Physician Oncology Board Review Manual is a study guide for fellows and practicing physicians preparing for board examinations in
More informationHORMONE THERAPY AND CHEMOTHERAPY
A SHARED DECISION-MAKING PROGRAM Early breast cancer HORMONE THERAPY AND CHEMOTHERAPY Are they right for you? BCA001B V06 Early breast cancer HORMONE THERAPY AND CHEMOTHERAPY Are they right for you? This
More informationAdjuvant Therapy for Breast Cancer: Questions and Answers
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Adjuvant Therapy for Breast
More informationFlorida Breast Health Specialists Breast Cancer Information and Facts
Definition Breast cancer is a cancer that starts in the tissues of the breast. There are two main types of breast cancer: Ductal carcinoma starts in the tubes (ducts) that move milk from the breast to
More information5.04.20. Perjeta. Perjeta (pertuzumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.04.20 Subject: Perjeta Page: 1 of 5 Last Review Date: June 19, 2015 Perjeta Description Perjeta (pertuzumab)
More informationNational Pharmaceutical Pricing Authority 3 rd Floor, YMCA Cultural Centre 1 Jai Singh Road New Delhi 110001 File No. 23(01)2014/Div.
Dated 21 st November 2014 NPPA Invites Comments of Pharmaceutical Industry & Trade, Consumer Organisations, Public Health Experts and other Stakeholders on the Recommendations of Tata Memorial Centre under
More informationRemember: Not everyone experiences these persistent and late side effects.
Persistent and Late Effects of Breast Cancer and Breast Cancer Treatment PMH You may have already experienced side effects from cancer and its treatment. Fortunately, most side effects are short-lived
More informationDECISION AND SUMMARY OF RATIONALE
DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Everolimus in combination with exemestane hormone therapy for oestrogen receptor positive locally advanced or metastatic
More informationAppendix One. HER2-positive early breast cancer, its treatment and prognosis
Appendix One. HER2-positive early breast cancer, its treatment and prognosis Breast cancer and HER2/neu over-expression Health need is one of PHARMAC s nine decision criteria (http://www.pharmac.govt.nz/pdf/231205.pdf
More informationBackground. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4
Abstract No. 4501 Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial R. Motzer, D.
More informationBefore, Frank's immune cells could
Before, Frank's immune cells could barely recognize a prostate cancer cell. Now, they are focused on it. Stimulate an immune response against advanced prostate cancer Extend median survival beyond 2 years
More informationCLINICAL POLICY Department: Medical Management Document Name: Opdivo Reference Number: CP.PHAR.121 Effective Date: 07/15
Page: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationBreast Cancer Treatment
Breast Cancer Treatment Most women with breast cancer will have surgery. The two common types of surgery are breast-conserving surgery and mastectomy. Breast Conserving Surgery A lumpectomy removes only
More informationGuidance for Industry
Guidance for Industry Cancer Drug and Biological Products Clinical Data in Marketing Applications U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationOI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ
OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ Study Overview Inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase
More informationtrastuzumab, 600mg/5mL solution for injection (Herceptin ) SMC No. (928/13) Roche Products Ltd
trastuzumab, 600mg/5mL solution for injection (Herceptin ) SMC No. (928/13) Roche Products Ltd 06 December 2013 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More information3. Chemotherapy. "Practice Guidelines for Breast Cancer" Research. Questions. NCCN/JCCNB Seminar in Japan January 13-14, 2007 January 26-27, 2008
NCCN/JCCNB Seminar in January 13-14, 2007 January 26-27, 2008 "Practice Guidelines for Breast Cancer" A Comparison between and (: as of 2007, : according to "Practice Guideline for Breast Cancer"(2005)
More informationTreating Recurrent Metastatic Breast Cancer
BREAST CANCER Treating Recurrent Metastatic Breast Cancer Presented by Julie Gralow, MD Fred Hutchinson Cancer Research Center Generosa Grana, MD UMDNJ/Robert Wood Johnson School of Medicine Patricia Spicer,
More informationEmerging Role of Aromatase Inhibitors in the Treatment of Breast Cancer
Emerging Role of Aromatase Inhibitors in the Treatment of Breast Cancer Review Article [1] March 02, 1998 By Harold A. Harvey, MD [2] The new generation of potent steroidal and nonsteroidal inhibitors
More informationPhase III trials in oncology
Phase III trials in oncology Setting standards of care? Siegfried Seeber and Ada H Braun* Survival data from phase III trials can be very misleading because patients are not offered the best follow-up
More informationGuideline for the Non Surgical Treatment of Breast Cancer
Guideline for the Non Surgical Treatment of Breast Cancer incorporating former guidelines for systemic treatment, radiotherapy and aromatase inhibitors. Version History Version Date Comments 2.0 20.02.08
More informationLOOKING FORWARD PUMA BIOTECHNOLOGY, INC. 2014 ANNUAL REPORT
LOOKING FORWARD PUMA BIOTECHNOLOGY, INC. 2014 ANNUAL REPORT Puma Biotechnology, Inc. is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of
More informationWhat is breast cancer?
Breast Cancer What is breast cancer? Let us explain it to you. www.anticancerfund.org www.esmo.org ESMO/ACF Patient Guide Series based on the ESMO Clinical Practice Guidelines BREAST CANCER: A GUIDE FOR
More informationLondon Cancer New Drugs Group APC/DTC Briefing
London Cancer New Drugs Group APC/DTC Briefing Continued use of trastuzumab following disease progression in metastatic breast cancer Contents Summary 1 Background 2 Adverse events/safety issues Health
More informationBREAST CANCER TREATMENT REGIMENS (Part 1 of 6)
BREAST CANCER TREATMENT S (Part 1 of 6) The selection, dosing, and administration of anticancer agents and the management of associated toxicities are complex. Drug dose modifications and schedule and
More informationIBRANCE is not approved for any indication in any market outside the U.S.
IBRANCE (palbociclib) Fact Sheet IBRANCE (palbociclib) is an oral inhibitor of cyclin-dependent kinases (CDKs) 4 and 6. IBRANCE is indicated in combination with letrozole for the treatment of postmenopausal
More informationChemotherapy for the treatment of advanced breast cancer
JULY 2010 Incorporates published evidence to December 2009 RECOMMENDATIONS FOR USE OF Chemotherapy for the treatment of advanced breast cancer A CLINICAL PRACTICE GUIDELINE DEVELOPED BY NATIONAL BREAST
More informationThe Impact of Taxotere on Adjuvant Breast Cancer
The Impact of Taxotere on Adjuvant Breast Cancer a report by Pierre Fumoleau and Henri Roché Centre Georges François Leclerc, Dijon, and Institut Claudius Regaud, Toulouse, France DOI: 10.17925/EOH.2005.0.0.1l
More informationFulvestrant in Heavily Pretreated Metastatic Breast Cancer: Is It Still Effective as a Very Advanced Line of Treatment?
Fulvestrant in Heavily Pretreated Metastatic Breast Cancer: Is It Still Effective as a Very Advanced Line of Treatment? Tamar Safra MD *, Julia Greenberg MD *, Ilan G. Ron MD, Rami Ben Yosef MD, Moshe
More informationEarly and Locally Advanced Breast
Early and Locally Advanced Breast Cancer Audrea H. Szabatura, Pharm.D., BCOP; and Amy Hatfield Seung, Pharm.D., BCOP Reviewed by Jared M. Freml, Pharm.D., BCOP; Clarence Chant, Pharm.D., BCPS, FCSHP; and
More informationThames Valley Cancer Network. Network Chemotherapy Protocols Breast Cancer
Network Chemotherapy Protocols Breast Cancer Notes from the editor Thames Valley Cancer Network These protocols are available on the Network website www.tvcn.nhs.uk. Any correspondence about the protocols
More informationMaintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai
Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s
More informationX-Plain Chemotherapy for Breast Cancer - Adriamycin, Cytoxan, and Tamoxifen Reference Summary
X-Plain Chemotherapy for Breast Cancer - Adriamycin, Cytoxan, and Tamoxifen Reference Summary Introduction Breast cancer is a common condition that affects one out of every 11 women. Your doctor has recommended
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PS Inj - Velcade Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antineoplastic Client: PS Inj Approval Date: 10/2/2004 Revision Date: 5/22/2007
More informationREFERENCE CODE GDHC256CFR PUBLICAT ION DATE SEPTEMBER 2014 HER2-POSITIVE BREAST CANCER CHINA DRUG FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC256CFR PUBLICAT ION DATE SEPTEMBER 2014 HER2-POSITIVE BREAST CANCER CHINA DRUG FORECAST AND MARKET ANALYSIS TO 2023 Executive Summary Sales for HER2-Positive Breast Cancer in China Market
More informationAvastin in Metastatic Breast Cancer
Non-interventional study Avastin in Metastatic Breast Cancer ML 21165 / 2007 Clinical Study Report Synopsis ROCHE ML21165 / WiSP Project RH09 / V. 1.0 / 24.06.2013 ROCHE ML21165-2 - Name of Sponsor Roche
More informationAnti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma. Claire Vines, 2016 Pharm.D. Candidate
+ Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma Claire Vines, 2016 Pharm.D. Candidate + Disclosure I have no conflicts of interest to disclose. + Objectives Summarize NCCN
More informationWhat is the optimal sequence of anti-her2 therapy in metastatic breast cancer?
What is the optimal sequence of anti-her2 therapy in metastatic breast cancer? David Miles Mount Vernon Cancer Centre Northwood Middlesex UKBCM mee)ng: London 2013 Herceptin plus a taxoid extends survival
More informationChemotherapy in Ovarian Cancer. Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group
Chemotherapy in Ovarian Cancer Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group Adjuvant chemotherapy for early stage EOC Fewer than 30% women present with FIGO stage
More informationAbstract Introduction. Aim of the study. Conclusion. Patients and methods. Keywords. Results. R. Abo El Hassan 1, M. Moneer 2
Original Study Outcome of HER2 positive luminal operable breast cancer in comparison with outcome of other operable luminal breast cancer patients: Long follow-up of single center randomized study R. Abo
More informationDRUG NAME: Pertuzumab
DRUG NAME: Pertuzumab SYNONYM(S): COMMON TRADE NAME(S): PERJETA CLASSIFICATION: monoclonal antibody Special pediatric considerations are noted when applicable, otherwise adult provisions apply. MECHANISM
More informationProportion of patients with invasive breast cancer in whom ER, PR and/or
1.1.a. Proportion of patients with invasive breast cancer in whom ER, PR and/or HER2 status assessment were performed 1.1.b. Proportion of patients with invasive breast cancer in whom systemic treatment
More informationLa Chemioterapia Adiuvante Dose-Dense. Lo studio GIM 2. Alessandra Fabi
La Chemioterapia Adiuvante Dose-Dense Lo studio GIM 2 Alessandra Fabi San Antonio Breast Cancer Symposium -December 10-14, 2013 GIM 2 study Epirubicin and Cyclophosphamide (EC) followed by Paclitaxel (T)
More informationTrastuzumab (Herceptin ) for patients with metastatic breast cancer
JULY 2007 Incorporates published evidence to November 2006 INFORMATION ABOUT Trastuzumab (Herceptin ) for patients with metastatic breast cancer This information has been developed to help you understand
More informationEffects of Herceptin on circulating tumor cells in HER2 positive early breast cancer
Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer J.-L. Zhang, Q. Yao, J.-H. Chen,Y. Wang, H. Wang, Q. Fan, R. Ling, J. Yi and L. Wang Xijing Hospital Vascular Endocrine
More informationCetuximab (Erbitux) MM.04.005 05/10/2005. HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s) of Service: Office: Outpatient
Cetuximab (Erbitux) Policy Number: Original Effective Date: MM.04.005 05/10/2005 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s)
More informationLONDON CANCER NEWS DRUGS GROUP RAPID REVIEW. FOLFIRINOX for first line treatment of advanced pancreatic cancer January 2012
Background LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW FOLFIRINOX for first line treatment of advanced pancreatic cancer January 2012 The incidence of pancreatic cancer in the UK is 9.4/100,000. It is
More informationA Phase 1 Study of MM-302, a HER2- targeted PEGylated liposomal doxorubicin, in Patients with HER2-positive Metastatic Breast Cancer (MBC)
A Phase 1 Study of MM-32, a HER2- targeted PEGylated liposomal doxorubicin, in Patients with HER2-positive Metastatic Breast Cancer (MBC) P LoRusso 1, I Krop 2, K Miller 3, C Ma 4, BA Siegel 4, AF Shields
More informationBreast Cancer Treatment Guidelines
Breast Cancer Treatment Guidelines DCIS Stage 0 TisN0M0 Tamoxifen for 5 years for patients with ER positive tumors treated with: -Breast conservative therapy (lumpectomy) and radiation therapy -Excision
More informationSMALL CELL LUNG CANCER
Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New
More informationActivity of pemetrexed in thoracic malignancies
Activity of pemetrexed in thoracic malignancies Results of phase III clinical studies of pemetrexed in malignant pleural mesothelioma and non-small cell lung cancer show benefit P emetrexed (Alimta) is
More informationLAPATINIB-BASED THERAPY FOR WOMEN WITH ADVANCED/ METASTATIC HER2 POSITIVE BREAST CANCER
146 Experimental Oncology 37, 146 150, 2015 (June) Exp Oncol 2015 37, 2, 146 150 LAPATINIB-BASED THERAPY FOR WOMEN WITH ADVANCED/ METASTATIC HER2 POSITIVE BREAST CANCER J. Zekri 1, 2, M. Mokhtar 3, S.M.
More information